Listar MD - Artículos por autor "Laborda-Illanes, Aurora"
Mostrando ítems 1-2 de 2
-
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo, Tamara; Lavado Valenzuela, Rocío; Jiménez-Rodríguez, Begoña; Pascual, Tomás; Gálvez, Fernando; Falcón, Alejandro; Álamo, María del Carmen; Morales-Estévez, Cristina; Amerigo, Marta; Pascual, Javier; Sánchez-Muñoz, Alfonso
; González-Guerrero, Macarena; Vicioso-Recio, Luis Prudencio; Laborda-Illanes, Aurora; Ortega-Jiménez, María Victoria; Pérez-Villa, Lidia; Fernández-Martínez, Aranzazu; Chic, Nuria; Jerez-Aragonés, José Manuel; Álvarez-Pérez, Martína; Prat, Aleix; Ribelles, Nuria; Alba-Conejo, Emilio[et al.] (Frontiers Media, 2019)
Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates ... -
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
Onieva Zafra, Juan Luis; Xiao, Qingyang; Berciano-Guerrero, Miguel Ángel; Laborda-Illanes, Aurora; de Andrea, Carlos; Chaves, Patricia; Piñeiro Pereda, María del Pilar; Garrido-Aranda, Alicia; Gallego-Domínguez, Elena María; Sojo, Belén; Gálvez Carvajal, Laura; Chica Parrado, María del Rosario; Prieto Cuadra, Juan Daniel; Pérez-Ruiz, Elisabeth; Farngren, Angela; Lozano, María José; Álvarez-Pérez, Martína; Jiménez, Pedro; Sánchez-Muñoz, Alfonso; Oliver, Javier; Cobo Dols, Manuel Ángel; Alba-Conejo, Emilio; Barragán, Isabel[et al.] (MDPI, 2022)
Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy, which otherwise demonstrates durable responses with acceptable toxicity scores. ...